More about

Thyroid Eye Disease

News
March 11, 2021
2 min read
Save

Shortage of Tepezza disrupts treatment of thyroid eye disease

Shortage of Tepezza disrupts treatment of thyroid eye disease

The COVID-19 pandemic has abruptly affected drug manufacturing in the United States. This now includes the production of Tepezza, the only FDA-approved medical therapy for thyroid eye disease.

News
March 10, 2021
1 min read
Save

Top in endocrinology: Thyroid eye disease, counteracting inactivity

Top in endocrinology: Thyroid eye disease, counteracting inactivity

Most patients with chronic thyroid eye disease had low quality of life despite receiving treatment or undergoing surgery, according to a recent survey. It was the top story in endocrinology last week.

News
March 01, 2021
2 min read
Save

Survey: Quality of life remains low in chronic thyroid eye disease

Survey: Quality of life remains low in chronic thyroid eye disease

Survey data show that the symptom burden of thyroid eye disease persists during the chronic phase of the disease, with most patients reporting continued low quality of life even after systemic glucocorticoid therapy or surgery.

News
February 15, 2021
1 min read
Save

Thyroid eye disease most prevalent in African American, white patients

Researchers found the highest prevalence of thyroid eye disease in African American and white patients in an evaluation of the American Academy of Ophthalmology IRIS Registry.

News
January 22, 2021
1 min read
Save

Endocrinology Drug and Device Update

In a review of the 2020 milestones, Endocrine Today compiled a list of drugs and devices related to the field that were newly approved, cleared and had label or indication changes.

News
December 16, 2020
2 min read
Save

Number of FDA new molecular entity approvals in 2020 similar to 2019

Number of FDA new molecular entity approvals in 2020 similar to 2019

Despite the COVID-19 pandemic, the FDA approved 47 new molecular entities in 2020, including one for ophthalmology, compared with 48 in 2019, according to a speaker at the virtual Ophthalmology Innovation Summit Year in Review meeting.

News
November 20, 2020
2 min read
Save

Data show longer-term efficacy of teprotumumab in severe, less severe thyroid eye disease

Additional data from the OPTIC-X extension trial and pooled analysis of phase 2 and 3 trial data confirm the efficacy of teprotumumab for the treatment of thyroid eye disease in the longer term and at different degrees of disease severity.

News
October 23, 2020
2 min read
Save

Teprotumumab confers long-term benefits in thyroid eye disease

Teprotumumab confers long-term benefits in thyroid eye disease

Adults with active thyroid eye disease assigned the human monoclonal antibody teprotumumab experienced improvements in disease outcomes that persisted nearly 1 year after receiving the last trial dose, new study data show.

News
September 04, 2020
2 min read
Save

Thyroid eye disease present in 40% of people with Graves’ disease

Thyroid eye disease present in 40% of people with Graves’ disease

Two of five people with Graves’ disease worldwide have thyroid eye disease, with higher rates among Asian populations vs. other ethnicities, according to a meta-analysis published in Clinical Endocrinology.

News
August 06, 2020
2 min read
Save

Survey highlights mental health impact of thyroid eye disease

Survey highlights mental health impact of thyroid eye disease

The increased focus on mental health amid the COVID-19 pandemic provides an important reminder to take stock of our patients’ mental health, as well as their physical health. This is especially critical for patients living with thyroid eye disease.

View more